GlassScriptPhysician profile
Kevin D Hale
NPI 1922101716
$6,108.73
in general payments reported to CMS, 2019-2025
56 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $606 · 2021: $865 · 2022: $910 · 2023: $1,086 · 2024: $943 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,356.82 | 2020-2025 | |
| Pfizer INC. | $423.73 | 2019-2025 | |
| Antares Pharma, INC. | $360.36 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $342.95 | 2020-2025 | Freestyle Libre 3, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $341.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $320.84 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $262.00 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $231.25 | 2019-2024 | Veozah |
| Horizon Therapeutics Plc | $220.95 | 2019-2022 | |
| Procept Biorobotics Corporation | $156.28 | 2024 | Aquabeam System |
| Sunovion Pharmaceuticals INC. | $143.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.12 | 2019-2023 | Glassia |
| Novartis Pharmaceuticals Corporation | $135.95 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.68 | 2019-2025 | Xifaxan |
Show all 55 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.